Nichol Ochsner | executive |
Neil McFarlane | executive |
R. Clifton | executive |
Louise Chen | analyst |
Joshua Schafer | executive |
Tim Lugo | analyst |
Oren Livnat | analyst |
Hello, and thank you for joining the Zevra Therapeutics Q2 2024 Financial Results and Corporate Highlights Call. Today's call is being recorded and will be made available on the company's website following the conclusion of the call. With that, I will now turn the call over to Nicole Oschner, Vice President of Investor Relations and Corporate Communications for Zevra Therapeutics.
Good afternoon, and thank you for joining us today to review Zevra Therapeutics progress in the second quarter of 2024 [Audio Gap]
is available in the Investors Section of the Zevra website.
As we begin our call, it's important to highlight that certain information covered in today's discussions will include forward-looking statements.